Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide. In addition to the liver-related morbidity and mortality, NAFLD is now also associated with various extrahepatic diseases. Pathogenesis of NAFLD is multifactorial with limited pharmacotherapy options for the treatment of patients with NAFLD. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that are involved in the transcriptional regulation of lipid metabolism, glucose homeostasis, energy balance, inflammation, and atherosclerosis. PPAR agonists are attractive options for treatment of NAFLD as they can act at multiple targets involved in the pathogenesis of NAFLD. We reviewed the available literature on the pathophysiological role of PPARs and use of PPAR agonists in the treatment of NAFLD. Original studies and review articles available on PubMed regarding the role of PPARs in the pathogenesis and utility of PPAR agonists in the treatment of NAFLD were included in this review article. ClinicalTrials.gov and Clinical Trials Registry-India sites were searched for ongoing studies on saroglitazar. The available literature suggests that PPARs play an important role in the pathogenesis of NAFLD. Use of PPAR gamma agonists is associated with histological improvement in NAFLD. Dual PPAR agonists with no or minimal PPAR gamma activity are being explored in the treatment of NAFLD. Because of the pathophysiological role of PPARs in NAFLD, PPAR agonists are attractive options for the treatment of patients with NAFLD. Dual PPAR agonists without significant gamma activity appear promising for the treatment of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107 · cited 1×
“In the liver, PPARb/d is well expressed in hepatocytes but is also expressed in Kupffer cells and hepatic stellate cells, suggesting a potential role in inflammation and fibrosis.(38) The PPARb/ d agonist, GW501516, has been shown to ameliorate obesity and insulin resistance in rats.”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“Weight gain happened significantly in the rosiglitazone arm, and dose reduction/discontinuation happened in some patients owing to painful swollen legs.(53) In the PIVENS trial involving patients with NASH randomized to receive pioglitazone, vitamin E, or a placebo for 96 weeks, pioglitazone demonstrated a reduction i…”
BackgroundCentral Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476 · cited 1×
“In the mice model, the PPARa agonist Wy-14643 prevented methionine and choline deficient (MCD) diet-induced hepatic triglyceride accumulation in WT mice, but it had no effect on PPARa / mice.(30) Fibrates are considered PPARa agonists, although less potent than the PPARa agonist Wy-14643.”
BackgroundStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“Journal of Clinical and Experimental Hepatology | November–December 201 demonstrated improvement in histologic features of NASH and decreased hepatic triglyceride content, along with reduced expression of inflammatory cytokines and fibrosis markers.(69) Elafibranor is an agonist of PPARa and PPARd.”
BackgroundA pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318 · cited 3×
“53).(55) TZDs are also associated with risk of cardiac adverse events.”
BackgroundInfluentialThiazolidinediones and Heart Failure
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · Diabetes Care · doi:10.2337/dc07-0141 · Cited by 262 · cited 1×
“Rosiglitazone is associated with more cardiac adverse events than pioglitazone.(57) The use of pioglitazone was found to be associated with risk of bladder cancer in RCTs (OR, 1.”
BackgroundA Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR
Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9072-3_22 · Cited by 222 · cited 1×
“PPARa also has anti-inflammatory effects through complex regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB).(18) The activation of PPARa occurs after dimerization with the RXR, resulting in formation of a multiprotein complex with protein coactivators.”
BackgroundIshibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · cited 1×
“Newer selective PPARa-specific agonists, known as selective PPARamodulators, are in different phases of development.(35,36)”
BackgroundTorres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
Serviddio, G., Giudetti, A. M., Bellanti, F., Priore, P., Rollo, T., Tamborra, R., Siculella, L., Vendemiale, G., Altomare, E., & Gnoni, G. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024084 · Cited by 128 · cited 1×
“Carnitine palmitoyltransferase 1 (CPT-1) is a pivotal enzyme that allows the FA to go through the inner mitochondrial membrane and reach the mitochondrial matrix for further metabolism.(20) Reduction of PPARa expression in the liver causes impairment of the transcription of its target gene CPT-1, and excessive FAs ten…”
BackgroundShan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97 · cited 2×
“Newer selective PPARa-specific agonists, known as selective PPARamodulators, are in different phases of development.35,36 N A FL D PPARb/d AND ITS AGONISTS PPARb/d is the least studied among all the PPAR isotypes, although it has significant expression in tissues controlling lipid metabolism, such as adipocytes, heart…”
MethodZhong, X., & Liu, H. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13853 · Cited by 60 · cited 1×
“Kupffer cells have proinflammatory (M1) and anti-inflammatory (M2) subtypes; thus, change toward the M2 subtype may prevent development of NAFLD.(47) TZDs are the most widely investigated PPARg agonists.”
BackgroundTreating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39 · cited 1×
“This normalization of the tricarboxylic acid cycle leads to decreased reactive oxygen species and cell damage signals, which should reduce inflammation and stellate cell activation.(66) Genetic (selective knockout) or pharmacologic targeting of the MPC by MSDC-0602K has been shown to increase insulin sensitivity and t…”
Background
Cited by
Berthier, A., Johanns, M., Zummo, F. P., Lefebvre, P., & Staels, B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166097 · Cited by 125
“…coding for isoforms of PPARγ (γ1, γ2, γ3) can be produced from the NR1C3 gene in a tissue-specific manner: Whereas PPARγ1 is ubiquitously expressed, PPARγ2 , the longest isotype, is expressed in both adipose tissues and liver and PPARγ3 is expressed mainly in colon and adipose tissue [9,10].”
BackgroundGoyal, O., Nohria, S., Goyal, P., Kaur, J., Sharma, S., Sood, A., & Chhina, R. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-78342-x · Cited by 83
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
Metadata
- Authors
- Choudhary, N. S., Kumar, N., & Duseja, A.
- Venue
- Journal of Clinical and Experimental Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 9
- Issue
- 6
- Pages
- 731-739
- ISSN
- 0973-6883 (ISSN-L)
- OpenAlex
- W2953485865
- Cited by
- 73
- References
- 24
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.